The magnitude of ERG-induced molecular and cellular changes, at least most of which are unrelated to cancer progression, may lead to an increased mitochondrial content in “fusion-type” prostate cancers, that masks demand for higher mitochondria content caused by specific molecular “progression events” requiring more mitochondrial function. Here, ERG is linked to prostate carcinoma.